Mar 13, 2014 - The phosphatidylinositol-3-kinase delta inhibitor idelalisib shows antitumor activity in patients with indolent non-Hodgkin's lymphoma and chronic lymphocytic leukemia, according to two studies published in the March 13 issue of the New England Journal of Medicine.